The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
These are among the best the industry has to offer.
Vertex Pharmaceuticals (VRTX) is a leading company in the cystic fibrosis (CF) medicines market, with no major patent cliff expected over the next decade. They are also making progress in kidney diseases, with povetacicept in Phase 3 trials and inaxaplin in investigational stages. Amgen (AMGN) has gained traction in 2026 due to its diverse portfolio of products, including MariTide, a promising weight-loss medicine.
Gilead Sciences (GILD) has a strong portfolio of HIV drugs, such as Biktarvy and Descovy for PrEP, and is also making strides in oncology with a robust pipeline. Exelixis (EXEL), while smaller than its competitors, has found success in the oncology market with Cabometyx, and is working on new cancer medicines and potential approvals for zanzalintinib.
Regeneron Pharmaceuticals (REGN) faced competition for its Eylea eye treatment, but has since rebounded with a new formulation and the strong performance of Dupixent. The company's diverse pipeline of programs, including weight-loss candidates, makes it an attractive investment. All of these biotech stocks exhibit strong potential and could be considered for investment without hesitation.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
